Skip to Content

Ascendis Pharma A/S ADR ASND

Morningstar Rating
$152.47 +4.71 (3.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ASND is trading at a 42% premium.
Price
$152.03
Fair Value
$669.60
Uncertainty
Very High
1-Star Price
$855.50
5-Star Price
$26.78
Economic Moat
Zhfkm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASND is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$147.76
Day Range
$147.58154.75
52-Week Range
$64.33161.00
Bid/Ask
$146.32 / $158.27
Market Cap
$8.63 Bil
Volume/Avg
461,966 / 609,920

Key Statistics

Price/Earnings (Normalized)
Price/Sales
29.74
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
879

Valuation

Metric
ASND
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
29.74
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ASND
Quick Ratio
2.31
Current Ratio
3.56
Interest Coverage
−10.14
Quick Ratio
ASND

Profitability

Metric
ASND
Return on Assets (Normalized)
−47.48%
Return on Equity (Normalized)
−786.88%
Return on Invested Capital (Normalized)
−66.57%
Return on Assets
ASND
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHtbl$550.4 Bil
VRTX
Vertex Pharmaceuticals IncXnkxkz$111.8 Bil
REGN
Regeneron Pharmaceuticals IncGbxbkh$107.9 Bil
MRNA
Moderna IncJfnx$36.3 Bil
ARGX
argenx SE ADRRvdjx$23.0 Bil
BNTX
BioNTech SE ADRRkh$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncYrsmgs$19.2 Bil
BMRN
Biomarin Pharmaceutical IncRcnjtcc$16.4 Bil
RPRX
Royalty Pharma PLC Class ASlhzv$13.4 Bil
INCY
Incyte CorpKsgrtvy$13.3 Bil

Sponsor Center